Ingrid Vandenborre and Caroline Janssens discuss recent investigations by antitrust agencies around the world of a variety of practices by life science companies, including alleged denigration of rivals’ products, price increases, biosimilar entry, delayed entry of generic medicines, collaboration agreements and local regulatory/procurement practices. The authors detail how enforcers regard these practices and where major jurisdictions concur, or not, in their analysis.
An extract from GCR’s The Guide to Life Sciences - First Edition. The whole publication is available at https://globalcompetitionreview.com/guide/guide-life-sciences/first-edition.